Halozyme Therapeutics, Inc. vs. Recursion Pharmaceuticals, Inc. Class A Common Stock
HALO
Halozyme Therapeutics, Inc.
$103.44 -15.88%
VS RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock
$3.68 -3.92%
Halozyme Therapeutics, Inc. and Recursion Pharmaceuticals, Inc. Class A Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| HALO | RXRX | |
|---|---|---|
| Market Cap | $13.96 billion | $2.29 billion |
HALO leads on 1 of 1 size & scale factors.
Risk & Sentiment
| HALO | RXRX | |
|---|---|---|
| Short Interest | 9.79% | 0.29% |
RXRX leads on 1 of 1 risk & sentiment factors.
Dig deeper: HALO overview, HALO financials, RXRX overview, RXRX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.